Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 7/20 | 0.41 |
| ▸ | CA1 | P00915 | 7/20 | 0.41 |
| ▸ | CA2 | P00918 | 7/20 | 0.41 |
| ▸ | CA9 | Q16790 | 7/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3193200 | 0.98 | TDP1 (0.47) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL1082707 | 0.91 | TDP1 (0.56) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL5182157 | 0.90 | TDP1 (0.50) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL27804545 | 0.90 | MAOA (0.43) | TDP1MAOAMAOBMEN1GAA | |
| Acrylamide SCHEMBL27782983 | 0.90 | MAOA (0.43) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL15684647 | 0.87 | TDP1 (0.44) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL10331453 | 0.86 | TDP1 (0.49) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL12707647 | 0.86 | TDP1 (0.41) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL31228191 | 0.85 | TDP1 (0.47) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL25014915 | 0.84 | TDP1 (0.50) | TDP1MAOAMAOBMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113633613-B | siRNA micelle, preparation method, composition and application thereof | 河南大学 | 2023-04-25 | — | — | CN | claimed |
| CN-1034077-C | Process for preparing pyrido [2, 3-f ] [1, 4] thiazepines | ORTHO PHARMA CORP (US) | 1997-02-19 | — | — | CN | claimed |
| EP-0462696-B1 | Novel pyrido [2,3-f][1,4] thiazepines and pyrido [3,2-b][1,5] benzothiazepines | ORTHO PHARMA CORP (US) | 1995-08-09 | — | — | EP | claimed |
| EP-0462696-A1 | Novel pyrido [2,3-f][1,4] thiazepines and pyrido [3,2-b][1,5] benzothiazepines | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-12-27 | — | — | EP | claimed |
| EP-4731602-A1 | NEW CLASS OF LIPIDS FOR DELIVERING ACTIVE INGREDIENTS INTO CELLS | OZ Biosciences (FR) | 2026-04-29 | — | — | EP | disclosed |
| US-20260053939-A1 | Combination Therapy for Cancer | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-02-26 | — | — | US | disclosed |
| US-20260041776-A1 | POLYMER CONTRAST AGENT | KOWA COMPANY, LTD. (JP) | 2026-02-12 | — | — | US | disclosed |
| US-20250368840-A1 | CORE-SHELL TEMPLATE MOLECULE/PARTICLE FOR TECHNIQUE FOR HIGH-YIELD FORMATION OF PORES ON SUBSTRATE | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-12-04 | — | — | US | disclosed |
| EP-4570837-A1 | POLYMER CONTRAST AGENT | KOWA COMPANY, LTD. (JP) | 2025-06-18 | — | — | EP | disclosed |
| US-20250116661-A1 | TECHNIQUE FOR ALIGNING PARTICLES ON SUBSTRATE WITHOUT AGGLOMERATION | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-04-10 | — | — | US | disclosed |
| CN-119677788-A | Polymer contrast medium | 兴和株式会社 | 2025-03-21 | — | — | CN | disclosed |
| CN-119528919-A | Biotin receptor targeting photosensitizer, preparation method and application thereof and kit containing biotin receptor targeting photosensitizer | 上海光声制药有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-1179963-C | Cephalosporin antibiotics, composition and application | ������ҩ��ҵ����˾ | 2004-12-15 | — | — | CN | disclosed |
| CN-1066735-C | Cephalosporin antibiotics | MICROCIDE PHARMACEUTICALS INC (US) | 2001-06-06 | — | — | CN | disclosed |
| CN-1291611-A | Cephalosporin antibiotics | MICROCIDE PHARMACEUTICALS INC (US) | 2001-04-18 | — | — | CN | disclosed |
| CN-1291612-A | Cephalosporin antibiotics | MAICROSEI MEDICINE CO (US) | 2001-04-18 | — | — | CN | disclosed |
| CN-1204336-A | Cephalosporin antibiotics | MICROCIDE PHARMACEUTICALS INC (US) | 1999-01-06 | — | — | CN | disclosed |
| EP-0462696-B1 | Novel pyrido [2,3-f][1,4] thiazepines and pyrido [3,2-b][1,5] benzothiazepines | ORTHO PHARMA CORP (US) | 1995-08-09 | — | — | EP | disclosed |
| EP-0462696-A1 | Novel pyrido [2,3-f][1,4] thiazepines and pyrido [3,2-b][1,5] benzothiazepines | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-12-27 | — | — | EP | disclosed |
| CN-1056880-A | Novel pyrido [2, 3-f ] [1, 4] thiazepines and pyrido [3, 2-b ] [1, 5] benzothiazepines | ORTHO PHARMA CORP (US) | 1991-12-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041776-A1 | POLYMER CONTRAST AGENT | RXFP3, HAX1, MSR1 | TDP1 2333/4885MAOA 3051/4885MAOB 3518/4885 |
| US-20260053939-A1 | Combination Therapy for Cancer | BCL6, PSMB6, PDCD6 | TDP1 1272/4885MAOA 4669/4885MAOB 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.